Combining this Ki-67 labeling pattern to histology, IHC, and EBV-specific assays may help reach a more conclusive pathological diagnosis of the cancer and help with the choice of adequate molecular tests for potential double hit/triple hit lymphomas. This evidence concerns the gene MKI67 and lymphoma.